Sentences with phrase «for cell therapy applications»

Unfortunately, most commercially available microcarriers have significant disadvantages that hinder their use for cell therapy applications.

Human mesenchymal stem cells (hMSCs) are currently the most common adult stem cell type used for cell therapy applications due to their regenerative properties and ability to differentiate into multiple cell lineages (adipocyte, chondro ¬ cyte, and osteocyte).

For cell therapy applications, a viable, functional cell is the desired product.

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Cambridge, MA — February 6, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application (IND) for the company's lead program, light - activated AU - 011 in ocular melanoma (OM).

Even more applications for cell therapies beyond cancer could become reality in the coming years.

To strengthen its clinical research profile, Dresden has created a strategic plan, to be funded by the German Research Ministry (BMBF), that focuses on three aspects of clinical research: tissue engineering and development of physical and molecular medical technologies for clinical application; therapeutic strategies after cell and tissue damage; and diagnosis and therapy of malignant diseases.

Using fluorescent dye, researchers figured out how to turn cells into lasers — with applications for cell tagging and tracking as well as medical diagnoses and therapies

«For the broad application of stem cell - derived pituitary cells in the future, cell replacement therapy may need to be customized to the specific needs of a given patient population,» Zimmer says.

Hydrogels, noted for their biomimetic properties, are the leading materials for biomedical applications, such as drug delivery and stem cell therapy.

For these cells to be as useful as embryonic stem cells, «we have to find a way to avoid retroviruses before application in cell therapy», Yamanaka says, as they could result in tumours.

The advent of molecular cloning, DNA sequencing and the many tools of molecular genetics and cell biology has given us sufficient knowledge of the basis for disease and the genes to target, but what has limited the application of gene therapy has been efficient gene delivery systems.

To the Editor: In their Clinical Review, Dr Burt and colleagues1 assessed clinical applications of adult stem cell therapies for nonmalignant diseases.

Furthermore, this study also encourages the application of iPSC - MSCs as an exciting new therapeutic option for a range of immunological disorders and suggests that further study of the secreted factors may allow the construction of efficient cell - free therapies in the near future.

Intellia is developing human gene and cell therapies for both ex vivo and in vivo applications using CRISPR - Cas9 gene editing technology.

In parallel to this cell therapy application, keratynocytes and melanocytes derived from pluripotent stem cells will be used for pathological modelling of genodermatoses allowing identification of new disease - specific pharmacological treatments

The symposium brings together leaders in biology, medicine, and industry to present on the latest advances in technology development, mechanistic understanding, and therapeutic application of stem cells for both drug development and cell - based therapy.

The long - term vision is to apply these technologies to other genetic diseases, such as sickle cell disease, and to explore applications in developing effective immune therapies for cancer.

«I highly respect Novocell technologies and am pleased to collaborate with Novocell and explore the potential of their hES cell to islet cell advances in combination with our iPS cells as a potential new sources for the generation of cellular models and therapies for diabetes,» said Dr. Yamanaka, Director of Center for iPS Research and Application at Kyoto University.

Allogeneic cell therapies involving primary cell types such as bone marrow mesenchymal stromal / stem cells (BM - MSCs), hematopoietic stem and progenitor cells (HSPCs), and T and natural killer (NK) cells for immunotherapy applications are especially challenging because of the vigorous process of screening...

The Bulte Lab has developed methods to label cells magnetically using tiny superparamagnetic iron oxide nanoparticles in order to make them visible by magnetic resonance imaging; this technology has now been introduced in the clinic for several cell therapy applications.

A promising clinical application for stem and progenitor cell transplantation is in rescue therapy for degenerative diseases.

«Finding this population of stem cells in a human source represents a major breakthrough for us because it brings us much closer to a clinical application of this therapy,» said Dr. Huard, the Henry J. Mankin Professor and vice chair for Research in the Department of Orthopaedic Surgery at the University of Pittsburgh School of Medicine.

Therefore, this work provides strong support for the use of iPSC ‐ derived MSC as a more uniform with well ‐ defined phenotype and function as a sustainable source of cells which paves the way for a clinical application for IBD cellular therapy.

It is conceivable the techniques being developed might have some application in future stem cell therapies in humans where a cloning process was used to generate particular tissues for transplantation.

Specifically, application of a prefabricated cardiac tissue patch to prevent dilation and to improve pumping efficiency of the infarcted heart offers a promising strategy for making stem cell therapy a clinical reality.

The advent of human induced pluripotent stem cells has been heralded as a major breakthrough in the study of pluripotent stem cells, for these cells have yielded fundamental insights into the reprogrammability of somatic cell fates, but also because of their seemingly great promise in applications, including potential uses in cell therapy.

Prof. Su's current research fields include the design, the synthesis, the property study and the molecular engineering of nanostructures and highly organized and hierarchically self - assembled porous materials, bio-integrated living and bio-inspired materials including leaf - like materials by the immobilization of living organisms and biomaterials for catalysis, photocatalysis, CO2 reduction and water splitting, artificial photosynthesis, nanotechnology, biotechnology, information technology, energy storage and conversion, cell therapy and biomedical applications.

Allogeneic cell therapies from primary cells for immunotherapy applications are especially challenging because of the vigor with which tissue donors must be screened and qualified to prevent transmission of infectious disease and ensure maintenance of an active donor pool.

Initially founded in 2011 as a Heart Institute, our treatment protocols were later expanded to include adult stem cell therapy for patients with severe and chronic medical needs that, per scientific research, clinical trials and application, can be safely and potentially efficaciously treated with patients» own stem and regenerative cells.

Sourcing Clinical - Grade Human Tissue: Considerations for Supporting Cell Therapy Development and Production Procuring donated human tissue for clinical applications is fraught with technical, ethical, and legal issues.

These two properties (self - renewal and pluripotency) confers human pluripotent stem cells a unique interest for clinical applications since they could allow the production of infinite quantities of cells for disease modelling, drug screening and cell based therapy.

NeuroStemcell, which comprises 13 academic partners and 2 SMEs and 1 Research Enterprise from 6 European countries and the United States of America, is formed to create a world - leading consortium that can develop stem cell based therapies for Parkinson's disease and Huntington's disease toward clinical application... Read more»

Given our extensive experiences in neuronal differentiation of hESCs [6], [7], [8] and the potential application of hESC - derived neurons in cell replacement therapies for neurodegenerative diseases, we designed a set of experiments aimed at developing a hESC - based automated assay for screening small molecules that have differential toxicity to hESC - derived NSCs and their differentiated neural progenies.

Importantly, because it is already approved for clinical use, amiodarone HCL may have clinical applications in cell replacement therapies by selectively removing only the unwanted undifferentiated NSCs during the pre-transplant period.

«The proposed experiments, if successful, will address an important unmet need in bringing stem cell therapies to clinical use and provide the foundation for a wide range of additional applications,» Clegg said.

In a review published in the Journal of Feline Medicine and Surgery, Jessica M. Quimby, DVM, Ph.D., DACVIM, Department of Veterinary Clinical Sciences at The Ohio State University, and Dori L. Borjesson, DVM, MPVM, Ph.D., Veterinary Institute for Regenerative Cures at the University of California, Davis, consider both the current and potential clinical applications of mesenchymal stem cell therapy in cats.

Preparation and global prosecution of patent applications directed to diagnostic and therapeutic products including antibodies, gene therapies, vaccines, stem cells, pharmaceutical formulations, nanotechnology, nucleic acid molecules, biologics, medical devices, mouse platforms for antibody development, and methods of treating diseases.